Thrombin-activatable fibrinolysis inhibitor and activated factor XII in patients with systemic lupus erythematosus

Thrombosis Research

Volumn 119, Issue 1, 2007, Pages 129-131

  Ringwald, Juergen ^a   Buettner, Stefanie ^a   Zimmermann, Robert ^a   Weisbach, Volker ^a   Strasser, Erwin ^a   Eckstein, Reinhold ^a   Eckel, Karin ^b   Manger, Karin ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; BLOOD CLOTTING FACTOR 12A; PLASMIN; THROMBIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR;

ADOLESCENT; ADULT; AGED; ANTICOAGULATION; ARTERY THROMBOSIS; BLOOD LEVEL; CARDIOVASCULAR RISK; CONTROLLED STUDY; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; STATISTICAL ANALYSIS; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOEMBOLISM; VENOUS THROMBOEMBOLISM;

ADOLESCENT; ADULT; AGED; CARBOXYPEPTIDASE U; CASE-CONTROL STUDIES; COHORT STUDIES; FACTOR XIIA; FEMALE; HEMOSTASIS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; THROMBOEMBOLISM;

EID: 33750818973     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2006.01.002     Document Type: Letter

References (12)

1. Esdaile J.M., Abrahamowicz M., Grodzicky T., Li Y., Panaritis C., du Berger R., et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 44 (2001) 2331-2337
2. Manger K., Kusus M., Forster C., Ropers D., Daniel W.G., Kalden J.R., et al. Factors associated with coronary artery calcification in young female patients with SLE. Ann Rheum Dis 62 (2003) 846-850
3. Sarzi-Puttini P., Atzeni F., and Carrabbba M. Cardiovascular risk factors in systemic lupus erythematosus and in antiphospholipid syndrome. Minerva Med 94 (2003) 63-70
4. Bajzar L., Manuel R., and Nesheim M.E. Purification and characterization of TAFI, a thrombin-activatable fibrinolysis inhibitor. J Biol Chem 270 (1995) 14477-14484
5. Van Tilburg N.H., Rosendaal F.R., and Bertina R.M. Thrombin activatable fibrinolysis inhibitor and the risk of deep vein thrombosis. Blood 95 (2000) 2855-2859
6. Libourel E.J., Bank I., Meinardi M.R., Balje-Volkers C.P., Hamulyak D., Middeldorp S., et al. Co-segregation of thrombophilic disorders in factor V Leiden carriers; the contributions of factor VIII, factor XI, thrombin activatable fibrinolysis inhibitor and lipoprotein(a) to the absolute risk of venous thromboembolism. Haematologica 87 (2002) 1068-1073
7. Mosnier L.O., Von dem Borne P.A., Meijers J.C.M., and Bouma B.N. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation. Thromb Haemost 80 (1998) 829-835
8. Donmez A., Aksu K., Ak Celik H., Keser G., Cagirgan S., Omay S.B., et al. Thrombin activatable fibrinolysis inhibitor in Behçet's disease. Thromb Res 115 (2005) 287-292
9. McLaren M., Alkaabi J., and Connacher M. Activated factor XII in rheumatoid arthritis. Rheumatol Int 22 (2002) 182-184
10. Manger K., Manger B., Repp R., Geisselbrecht M., Geiger A., Pfahlberg A., et al. Definition of risk factors for death, end stage renal disease, and thromboembolic events in a monocentric cohort of 338 patients with systemic lupus erythematosus. Ann Rheum Dis 61 (2002) 1065-1070
11. Hochberg M.C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40 (1997) 1725
12. Zito F., Drummond F., Bujac S.R., Esnouf M.P., Morrissey J.H., Humphries S.E., et al. Epidemiologic association of activated factor XIIa concentration with factor VII activity, fibriniopeptide A concentration, and risk of coronary heart disease in men. Circulation 102 (2000) 2058-2062